PAUL S DENKER
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism PALM HARBOR, FL NPI 1750328811
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism FL Amgen Inc. All categories
General Payments — all program years on this page
$18,527.99
- Category: General Payments
- Program years: PY2018–2024
- Record count: 925
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,624.19 across 79 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,624.19 | 79 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $223.22 | 11 |
| Novo Nordisk AS | $170.76 | 9 |
| UCB, Inc. | $104.60 | 6 |
| MannKind Corporation | $103.54 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $98.54 | 5 |
| BETA BIONICS, INC. | $91.43 | 4 |
| Corcept Therapeutics | $81.92 | 5 |
| Abbott Laboratories | $72.70 | 4 |
| IBSA Pharma Inc. | $71.92 | 3 |
| Insulet Corporation | $63.59 | 3 |
| Antares Pharma, Inc. | $60.57 | 3 |
| Lilly USA, LLC | $57.52 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $53.85 | 3 |
| Alexion Pharmaceuticals, Inc. | $52.27 | 2 |
| DEXCOM, INC. | $45.01 | 2 |
| Nevro Corp. | $44.10 | 2 |
| Xeris Pharmaceuticals, Inc. | $31.46 | 1 |
| Aurinia Pharma U.S., Inc. | $30.47 | 1 |
| Ultragenyx Pharmaceutical Inc. | $26.10 | 1 |
| CeQur Corporation | $25.69 | 1 |
| SANOFI-AVENTIS U.S. LLC | $23.33 | 1 |
| Regeneron Healthcare Solutions, Inc. | $20.73 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.51 | 1 |
| Avvisto Therapeutics, LLC | $18.02 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $17.21 | 1 |
| Radius Health, Inc. | $17.13 | 1 |
By program year
Records — PY2024 (79)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.